Last update Aug. 24, 2022

Rurioctocog Alfa Pegol

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Coagulation factor IX or Antihemophilic Factor is a plasma glycoprotein consisting of 2,300 amino acids that is used to treat hemophilia B (factor VIII deficiency). It can be obtained from human plasma or produced by recombinant DNA technology (Efmoroctocog Alfa, Moroctocog Alfa, Octocog Alfa, Rurioctocog Alfa, Simoctocog Alfa, Susoctocog alfa, Turoctocog Alfa ), or as a pegylated derivative (Rurioctocog Alfa Pegol). Intravenous administration.

Since the last update we have not found published data on its excretion in breastmilk.

Its very high molecular weigh make it highly unlikely that significant quantities will pass into breast milk.

Due to its protein nature, it is inactivated in the gastrointestinal tract, and is not absorbed, (it has virtually no oral bioavailability), which hinders or prevents its transfer from breastmilk to infant, except in premature babies and the immediate neonatal period, when there may be greater intestinal permeability.

Expert authors consider the use of this medication probably compatible during breastfeeding. (Hale). Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs: compatible with Breastfeeding. (WHO 2002)


We do not have alternatives for Rurioctocog Alfa Pegol since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.


Rurioctocog Alfa Pegol belongs to this group or family:


Main tradenames from several countries containing Rurioctocog Alfa Pegol in its composition:


Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 480.000 daltons
VD 0.03 - 0.04 l/Kg
Tmax 14.8 (12 - 20) hours


  1. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from Consulted on March 17, 2022 Full text (link to original source)
  2. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Full text (link to original source) Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM